Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial

Acta Oncol. 2022 Jul;61(7):869-873. doi: 10.1080/0284186X.2022.2079959. Epub 2022 May 31.

Ellen Backlund^{1

2}, Muyi Yang², Vitali Grozman^{3

4}, Giuseppe Masucci², Johan Falkenius², Hanna Eriksson^{1

2}, Braslav Jovanovic², Katarina Hammarlund¹, Ulf Isacsson^{5

6}, Calin Radu⁶, Edvard Abel⁷, Kristin Karlsson^{2

8}, Ricardo Palanco Zamora^{2

8}, Peter Wersäll^{1

2}, Ulrika Edbäck², Stina Wickström², Eva Darai Ramqvist⁹, Suzanne Egyhazi Brage², Rolf Kiessling², Kristina Viktorsson², Bo Franzén², Rolf Lewensohn², Roger Olofsson Bagge¹⁰, Gustav J Ullenhag^{6

11}, Lars Ny⁷, Karin Lindberg^{1

2}, Hildur Helgadottir^{1

2}

¹ Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.
² Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
³ Department of Diagnostic Radiology, Karolinska University Hospital, Sweden.
⁴ Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
⁵ Medical Radiation Physics, Uppsala University Hospital, Uppsala, Sweden.
⁶ Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
⁷ Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
⁸ Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.
⁹ Department of Clinical Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden.
¹⁰ Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
¹¹ Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.

No abstract available

Publication types